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Abstract 
Thyroid eye disease (TED) is a potentially sight-threatening and cosmetically 
disfiguring condition arising in 25-50% of patients with Graves' hyperthyroidism. 
CIRTED is the first study to evaluate the long-term role of radiotherapy and prolonged 
immunosuppression with azathioprine in treating TED, one aim of which was to 
validate the use of the English version of GO-QOL in an UK population with TED. In a 
three stage design over a 48 week period, the GO-QOL was tested and compared to a 
general measure of quality of life (WHOQOL-Bref). In stage 1 utilising a standard 14 day 
test-retest design both GO-QOL subscales achieved Cronbach’s alphas demonstrating 
excellent validity and internal reliability (Visual Function 0.929 and 0.931; Appearance 
0.888 and 0.906). In stage 2, Repeated Measures ANOVA demonstrated longitudinal 
validity, with both subscales of the GO-QOL showing significant change over time 
(Visual Function, η2=0.114, p<.001; Appearance, η2=0.069, p<.002). In stage 3 the GO-
QOL showed discriminant validity at the week 48 time point, with the visual function 
subscale being able to detect changes in groups identified by clinicians (using BCCOM 
ratings of improvement or deterioration), while both subscales could detect group 
differences when based on participants’ subjective ratings of TED noticeability and 
severity. The results of this project provide support for the English translation of the 
GO-QOL as an outcome measure for patients with moderately severe active Graves' 
orbitopathy/TED. 
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Introduction 
Graves’ ophthalmopathy or orbitopathy (GO) also known as thyroid eye disease (TED) 
is a potentially sight-threatening and cosmetically disfiguring condition arising in 25-
50% of patients with Graves' hyperthyroidism (Bahn & Heufelder, 1993). The condition 
is rare and causes redness and grittiness of the eye and can lead to disfiguring swelling 
of the eyelids, proptosis (abnormal protrusion or displacement of the eye) and even 
blindness (Weetman, 1991). GO is an autoimmune disorder, linked to thyroid 
autoimmunity by autoantigens shared between the thyroid and the orbit of the eye 
(Perros, Crombie & Kendall-Taylor, 1995).  Inflammatory processes are activated and 
fibroblasts in the eyes’ orbital tissue become stimulated leading to orbital tissue 
swelling, hyaluronan production, and expansion of the extraocular muscles, retro-
orbital fat and connective tissues (Khoo & Bahn, 2007). 
  
Currently the management of GO/TED is considered suboptimal, and available 
treatments do not specifically target the underlying pathogenic process (Bartalena et al, 
2016). The Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease 
(CIRTED) trial was designed to assess the effect of using radiotherapy and the 
immunosuppressive drug azathioprine in combination with standard prednisolone 
treatment (Rajendram et al, 2008). CIRTED is the first study to evaluate the long-term 
role of radiotherapy and prolonged immunosuppression with azathioprine in treating 
GO/TED.  
 
It is well established that TED can have a major impact on quality of life, in particular 
disfiguring changes to the eyes and face which can have a direct impact on psychological 
health (Coulter, Frewin, Krassas & Perros, 2007). As the aim of treating GO/TED is to 
improve patients’ visual function as well as making them look and feel better, it is 
important to assess the patients’ perception of these markers as part of a clinical trial. 
The GO-QOL questionnaire was developed by Terwee, Gerding, Dekker, Prummel & 
Wiersinga (1998) as a TED specific quality of life questionnaire that can be used as an 
outcome measure for studies and may also be of use in clinical practice. Marcocci et al 
(2011) tested the use of selenium in mild GO and used the GO-QOL to evaluate quality of 
life outcomes. They showed a correlation that indicated that as participants’ improved 
with selenium treatment their quality of life also improved, as measured by the GO-QOL.  
 
The aim of this three stage project was to validate the use of the English version of GO-
QOL in an UK population with TED. The GO-QOL is available in both English and Dutch; 
the Dutch version having previously been validated in the Netherlands (Terwee et al, 
1999). In the first stage of the work, the internal validity and test-retest study, the 
objective was to assess the consistency of the GO-QOL in measuring functional and 
appearance-related issues resulting from TED over a 14 day period where the 
expectation is that scores on both administrations should be correlated.  
 
In the second stage, we measured longitudinal validity i.e. the responsiveness of the GO-
QOL to changes in TED post-treatment against a more general measure of quality of life 
(in this case, the WHOQOL-Bref; The WHOQOL Group, 1998). This work had two aspects: 
 
1. If the GO-QOL is valid (i.e. sensitive to changes in visual functioning and appearance as 
a result of TED) we would expect larger effect sizes for the GO-QOL than for the general 
quality of life measure (WHOQOL-Bref).   
 
2. Furthermore, changes in clinical characteristics relating to visual functioning and 
appearance, as indicated by transitional variables, should be more closely associated 
with changes in scores on the relevant subscales of the GO-QOL than with the 
WHOQOL-Bref. 
 
The third and final stage was to explore the extent to which the GO-QOL can 
demonstrate discriminant validity. That is, whether the GO-QOL can distinguish 
between patient populations based on either clinician ratings of improvement or 
participants’ subjective measures. Although it should be noted that subjective severity 
does not always correlate well with objective measures of disease and physicians’ 
assessments (Bessell, Dures, Semple & Jackson, 2012). 
 
Methods 
Design 
The study protocol has been described in detail previously (Rajendram et al, 2008). In brief, 
CIRTED is a 2x2 factorial design, double-masked, multi-centre, randomized controlled 
trial (see Figure 1 for a diagram of the trial design).  
 
Ethical approval 
Ethical approval was from the UK’s National Health Service South West Central Bristol 
Research Ethics Committee (REC reference: 05/Q2006/62). Clinical Trial Authorisation was 
given by the Medicines and Healthcare products Regulatory Agency (MHRA, reference: 
03299/0003/001-0001; ISRCTN22471573) with the University of Bristol acting as the legal 
sponsor. Research governance and local Research and Development approvals were obtained 
across all sites prior to the start of recruitment. All participants gave written informed consent.  
 
[Figure 1 near here] 
 
Materials (see also Table 1) 
The Graves' ophthalmopathy quality of life assessment (GO-QOL) questionnaire consists 
of two subscales, each comprising eight questions, on visual function and the 
psychological impact of changed appearance (Terwee et al, 1998).  
 
The WHOQOL-Bref is a widely used and previously validated measure of quality of life 
consisting of 28 items which cover subjective overall quality of life and subjective 
overall health, plus items relating to domains of physical, psychological, social 
relationships and environment (The WHOQOL Group, 1998). The WHOQOL-Bref has 
been widely used with a range of populations and is reported to have good 
psychometric properties (Skevington, Lotfy & O’Connell, 2004). 
 
Two transitional variables relating closely to the subscales of the GO-QOL were included 
at follow up as an external standard to identify changes post-treatment (labelled “T1” 
and “T2”). These variables were agreed with the authors of the GO-QOL as being 
suitable for this purpose. In order to explore the impact of TED and its treatment on 
psychological adjustment and daily functioning more broadly, Visual Analogue Scales 
(VAS) were also included in the study. VAS scales are easy for respondents to complete 
and are often used in clinical assessments (Carr, 1997). 
 
Clinician ratings of disease severity and activity were also included. The Binary 
Composite Clinical Outcome Measure (BCCOM) a system of major and minor criteria used 
in previous TED trials (Prummel et al, 2004; Marcocci et al, 2001; Mourits et al, 2000). It is 
a clinician rating of improvement in the CIRTED trial used at 1 year post treatment to 
classify study participants’ treatment as being successful or not (see Appendix 1 for 
information on its derivation).  
 
[Table 1 near here] 
 
Protocol & Participants 
All participants referred to a trial centre during the duration of the study were 
considered for inclusion. Participants were prescribed a high dose of tapering 
prednisolone at their initial enrolment visit. If they were eligible, responded to steroids 
and not excluded, participants were randomized into one of four trial arms (see Figure 
1, Table 2, and CIRTED study protocol – Rajendram et al, 2008).  
 
For validating test-retest reliability, participants completed the GO-QOL twice at a two-
week interval, time point 1 (-2 weeks, i.e. enrolment into the study) and time point 2 (0 
weeks, i.e. randomization into the study). Two weeks have previously been used by 
Terwee et al (1999) for assessing test-retest reliability, as it is long enough to avoid 
recall bias and short enough for patients not to experience clinically important changes 
in their condition. Data from participants for the longitudinal validity testing was 
collected at all four time points. 
 
[Table 2 near here] 
 
Results 
The results are reported in the three stages that the work was undertaken. All analyses 
were undertaken using SPSS version 23. 
 
Stage 1 GO-QOL validation: internal validity and test re-test 
167 participants attended for study enrolment, while 133 attended the randomization 
appointment. Of these, 142 participants completed the GO-QOL at study enrolment, and 
126 completed the GO-QOL at randomization (see Table 3).  
 
[Table 3 near here] 
 
Item response tables for time points 1 (-2 weeks, enrolment) and 2 (0 weeks, 
randomisation) were generated to identify patterns of responses and are shown in 
Tables 4 & 5.  
 
[Tables 4 & 5 near here] 
 
Not all participants cycled or drove, hence the lower number of responses to questions 
1 and 2 on the Visual Function subscale at both time points. As per the questionnaire 
authors’ instructions (Terwee et al, 1998), adjustments for missing data were made 
when totalling the raw scores for each subscale prior to transforming them into a total 
score out of 100 for subsequent analyses. 
Internal validity was assessed using Cronbach’s alpha calculations; at time 1 (-2 weeks, 
enrolment) the visual function subscale achieved a Cronbach’s alpha score of 0.929 (CI 
0.909 – 0.944) while the appearance subscale recorded 0.888 (CI 0.857 – 0.912). At time 
2 (week 0, randomization), the alpha results for visual function remained virtually 
unchanged at 0.931 (CI 0.912 – 0.946), while the appearance subscale improved slightly 
to 0.906 (CI 0.880 – 0.926). This indicates good internal validity of the subscales at both 
time points, with values over 0.7 generally acceptable for psychometric questionnaires 
(BPS, 1992).  
 
Pearson correlation coefficients for both subscales were found to be highly significant 
(visual function, r=0.774, p<.001; appearance, r=0.862, p<.001), indicating the robust 
test-retest reliability of the GO-QOL subscales.  
 
Stage 2: Longitudinal validation of GO-QOL  
Longitudinal validation was performed using data from the 126 participants that were 
randomised into the trial (Table 6).  
 
[Table 6 near here] 
 
In this second stage, we measured the responsiveness of the GO-QOL to changes in TED 
post-treatment against the WHOQOL-Bref (a more general measure of quality of life). 
We hypothesized that, if the GO-QOL is sensitive to changes in visual functioning and 
appearance as a result of TED we would expect larger effect sizes for the GO-QOL than 
for the general measure (WHOQOL-Bref). Effect size was quantified using partial eta 
squared where the following thresholds can be used to determine effect size 
interpretation: η2  of less than 0.01 indicates an inconsequential effect, η2  between 0.01 
and 0.09 a small effect, η2 between 0.09 to 0.25 a medium effect, η2 from 0.25 to 0.50 a 
large effect, and η2 over 0.50 a very large effect (Cohen, 1988). 
 
Of the 126 randomized participants, 108 participants provided enough completed 
questionnaire data at the 12 week trial appointment, while 100 of those participants 
who attended the 48 week appointment completed the study measures (see Table 7). 
 
[Table 7 near here] 
For the sake of completeness, internal validity was assessed again using Cronbach’s 
alpha calculations; at both time 3 (short term 12 week trial appointment) and time 4 
(long term 48 week appointment). At time 3 the visual function subscale achieved a 
Cronbach’s alpha score of 0.904 (CI 0.854 – 0.937) while the appearance subscale 
recorded 0.918 (CI 0.891 – 0.938). At time 4 the alpha result for visual function had 
reduced slightly to 0.887 (CI 0.823 – 0.928), while the appearance subscale remained 
largely unchanged at 0.915 (CI 0.886 – 0.937). As before, with all values over 0.7 this 
indicates good internal validity of the subscales at both time points.  
 
Repeated measures ANOVA (with time as 3 level factor, i.e. -2, 12, and 48 weeks) 
revealed significant changes over time for both GO-QOL subscales (Visual Function, 
p=0.001, Appearance, p=0.002), and for the psychological domain of the WHOQOL 
(p=0.002). Effect sizes varied between the subscales for the GO-QOL with only Visual 
Function recording a medium effect size (η2=0.114); the Appearance subscale showed a 
small effect size (η2=0.069). Effect sizes for the WHOQOL subscales were all small 
(psychological, η2=0.064; physical, η2=0.037; social, η2=0.041; environment, η2=0.043) 
(Table 8).  
 
[Table 8 near here] 
 
We also hypothesized that changes in clinical characteristics relating to visual 
functioning and appearance, as indicated by the transitional variables, should be more 
closely associated with changes in scores on the relevant subscales of the GO-QOL than 
with the WHOQOL-Bref. As expected since all study participants were taking steroid 
treatment, correlation calculations showed positive correlations between both the 
transitional variables (T1 and T2) and the GO-QOL appearance subscale at the 12-week 
time point, while the Visual Function subscale only correlated with T1 (Table 9). 
Similarly, three of the WHOQOL-Bref subscales significantly correlated with T1, while 
all four subscales significantly correlated with T2. At 48-weeks significant correlations 
were observed only for the appearance subscale of the GO-QOL with the transitional 
variables. 
 
We included two Visual Analogue Scales to explore the impact of treatment for TED on 
psychological adjustment and daily functioning more broadly. At 12 weeks significant 
correlations were observed between both VAS scales and the appearance subscale of 
the GO-QOL. Three of the four domains of the WHOQOL-Bref significantly correlated 
with the VAS for participant perceived noticeability of TED (psychological, physical and 
environment), while a different trio of domains significantly correlated with the VAS for 
participant ratings of severity of TED (physical, social and environment). At 48 weeks, 
the only significant correlations observed were between both VAS scales and the 
appearance subscale of the GO-QOL. 
 
[Table 9 near here] 
 
Stage 3 Exploring discriminant validity and the relationships between subjective 
and objective measures of disease severity 
The third and final stage was to explore the discriminant validity of the GO-QOL as well 
as the relationships between the subjective and objective clinical measures for TED 
used in this study. 
 
Clinician ratings on BCCOM at the 48 week time point were used to split participants 
into two groups: condition has deteriorated (-1, N=58), or improved (+1, N=36; Table 
10). Analyses were then undertaken to determine any differences in mean GO-QOL 
scores between these groups. It might be expected that there would be differences 
between the mean changes (pre/post-treatment) in GO-QOL scores depending on 
whether clinicians reported visual functioning/appearance having either deteriorated 
or improved; i.e. we would expect larger increases in scores on the GO-QOL for those 
participants where clinician’s reported an improvement compared to those for whom 
they did not. 
 
[Table 10 near here] 
 
Independent samples t-tests were undertaken to determine differences between the 
groups on both the GO-QOL and WHOQOL measures while effect sizes were calculated 
using Cohen’s d (Cohen, 1988). For broad interpretation purposes threshold values for 
statistically significant effects for the statistic, d are: 0 < d < 0.1 a trivial effect; 0.1 < d < 0.2 a 
small effect; 0.2 < d < 0.5 a moderate effect; 0.5 < d < 0.8 a medium size effect; 0.8 < d < 
1.3 a large effect; 1.3 < d < 2.0 a very large effect; while d > 2.0 is a huge effect. However, 
these are, at best, guidelines and the value of d is very much context dependent.  
 
The independent samples t-tests showed a significant difference for the Visual Function 
subscale at 48-weeks (p=0.006) with a medium effect size (d=0.6; Table 11). Although 
no similar statistically significant difference was seen for the Appearance subscale at 
the same time point a moderate effect size was recorded (d=0.3). Similarly, no 
statistically significant differences between WHOQOL domain scores were observed for 
the BCCOM groups at the same time point, and effect sizes ranged from small (d=0.2 for 
the physical and environment domains) to moderate and medium (d=0.4 and 0.5 for the 
psychological and social domains, respectively). 
 
[Table 11 near here] 
 
The cohort was also split in relation to the scores achieved on the two Visual Analogue 
Scales, where 5.1 was used as the cut off to identify those of the 100 (where we had 
these data at week 48) who rated themselves as still having TED that was either 
noticeable or severe. When analysed according to these groupings, the subscale 
domains of the WHOQOL still showed no significant differences, but in relation to 
perceived noticeability of TED both subscales of the GO-QOL showed statistical 
significantly differences (p<.001) with a medium effect size for the Visual Function 
subscale (d=0.8) and a very large effect size for the Appearance subscale (d=1.6; Table 
12). In relation to groupings based on perceived severity of TED both subscales of the 
GO-QOL showed statistical significantly differences (p<.001), and again a medium effect 
size for the Visual Function subscale (d=0.8) and a very large effect size for the 
Appearance subscale (d=1.2; Table 12). 
 
[Table 12 near here] 
 
So it would seem that the GO-QOL does indeed demonstrate discriminant validity, 
although there is some suggestion in these data, that it may be dependent on the 
grouping variable utilised. The clinician ratings (BCCOM) and participant subjective 
ratings (VAS scales) were broadly similar in their results for the Visual Function 
component of the GO-QOL, but to distinguish in relation to appearance issues, it would 
seem that using participant ratings results in stronger, statistically significant 
differences. 
 
Discussion 
The results of this project support both the internal validity and reliability of the English 
translation of the GO-QOL as an outcome measure for patients with moderately active 
Graves' orbitopathy. Longitudinal validity has also been confirmed, with the GO-QOL 
being more sensitive to changes in TED over time than the more general WHOQOL-Bref., 
whilst also being associated with generally larger effect sizes, with both measures show 
an improving trend for the study participants over time. This longitudinal pattern of 
change for the subscales of the GO-QOL has also been shown over a 24 week period in a 
recent study testing Teprotumumab for thyroid-associated ophthalmology (Smith et al, 
2017). While both subscales of the GO-QOL showed significant change over time in 
Smith et al’s study, the Visual Function subscale was the one with the greatest change 
over time, as also suggested in our data. 
 
The analysis with the transitional variables is more equivocal. The hypothesized 
changes in clinical characteristics were generally associated with significant 
correlations for both quality of life measures with the transitional variables at the 12 
week time point. By the 48 week time point only the GO-QOL appearance subscale 
recorded significant correlations with the T1 (my eye condition causes me pain and 
discomfort) and T2 (my eye condition limits my ability to do the things I want to do). 
Given the focus of the T1 and T2 variables on what might be considered to be issues 
more associated with visual function, it is curious that the observed correlations are 
with the appearance subscale. The Visual Analogue Scales in the study are more focused 
on what might be considered appearance issues – the perceived noticeability and 
severity of the TED. It is probably no surprise that these were significantly correlated 
with the appearance subscale of the GO-QOL at both the 12 week and 48 week study 
time points.  
 
The GO-QOL has also demonstrated discriminant validity, with the visual function 
subscale being able to detect changes in groups identified by clinicians (using BCCOM 
ratings of improvement or deterioration), while both subscales could detect group 
differences when based on participants’ ratings of TED noticeability and severity. It is 
worth noting that BCCOM is constructed to include factors such as diplopia which 
would correlate much better with function than with appearance (Appendix 1). It has 
been suggested that patients with TED overrated the extent to which their appearance was 
affected, while endocrinologists underrated it (Terwee et al, 2003). Of course, the measures 
employed do not necessarily take into account the reference point, i.e. patients are possibly 
comparing themselves prior to TED, or with other people who do not have the disease at all, 
whereas clinicians could be comparing across individuals who have TED. Without 
interviewing the participants and clinicians concerned it is impossible to know. 
 
Historically health care professionals have found it difficult to engage with patients’ 
concerns regarding their looks and body image (Bessell et al, 2012), quantifying these 
concerns with a measure like the GO-QOL may help doctors’ engagement with their 
patients concerns and target therapy accordingly. 
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APPENDICES 
 
Appendix 1 
 
Binary composite clinical outcome measure (BCCOM) 
 
The BCCOM is a binary outcome with a positive result with no deterioration vs no 
change or deterioration in any component of the score.  
 
 
Major Criteria  
▪ An improvement of ≥ 1 grade in diplopia score* 
▪ An improvement of >8 degrees of eye movement in any direction#  
▪ A reduction of ≥ 2 mm in proptosis  
 
Minor Criteria  
▪ A reduction of ≥ 2 mm in lid aperture  
▪ An improvement of ≥ 1 grade in soft tissue involvement† 
▪ An improvement in best-corrected visual acuity of ≥ 1 line on the Snellen chart·  
▪ Subjective improvement^ 
 
Response to Treatment  
Very good: ≥ 2 major criteria  
Good: 1 major criterion  
Fair: ≥ 2 minor criteria  
No Change: 1 minor criterion  
Worse: Deterioration in at least 1 major or 2 minor criteria 
 
 
* Bahn, R. S., & Gorman, C. A. (1987). Choice of therapy and criteria for assessing 
treatment outcome in thyroid-associated ophthalmopathy· Endocrinology and 
metabolism clinics of North America, 16(2), 391-407. 
 
# Haggerty, H., Richardson, S., Mitchell, K. W. Dickinson, A. J. (2005). A modified method 
for measuring uniocular fields of fixation: reliability in healthy subjects and in patients 
with Graves orbitopathy· Archives of ophthalmology, 123(3), 356-62. 
 
† Dickinson, A. J., & Perros, P. (2001). Controversies in the clinical evaluation of active 
thyroid-associated orbitopathy: use of a detailed protocol with comparative 
photographs for objective assessment· Clin Endocrinol, 55(3), 283-303. 
  
^ Marcocci, C., Bartalena, L., Tanda, M. L., Manetti, L., Dell-Unto, E., Rocchi, R., … 
Pinchera, A. (2001). Comparison of the effectiveness and tolerability of intravenous or 
oral glucocorticoids associated with orbital radiotherapy in the management of severe 
Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. 
Journal of Clininical Endocrinology & Metabolism, 86(8), 3562-7. doi: 
http://dx.doi.org/10.1210/jcem.86.8.7737 
 
Table 1. Overview of the standardised questionnaires.  
Measure Description 
Standardised questionnaires 
GO-QOL - TED specific quality of life measure, validated in the 
Netherlands 
- 2 subscales: ‘visual function’ & ‘appearance’ comprising 
8 questions each 
- each item is scored as follows: 1= not impaired; 2=a 
little impaired; 3=severely impaired 
- raw scores are transformed to give a total out of 100 for 
each subscale 
-  higher scores indicate greater quality of life 
 
WHOQOL-Bref - general quality of life measure, validated for use in the 
UK 
- 4 subscales: psychological, physical, social and 
environmental; 28 questions in total 
- scored on a 5-point Likert scale 
- raw scores are transformed to give a total out of 100 for 
each subscale 
- higher scores indicate greater satisfaction with life 
 
Transitional variables 
T1 - is a single item: “My eye condition causes me physical 
pain/discomfort” 
- scored as follows: 1= never/almost never; 
2=sometimes; 3=often; 4=almost always 
T2 - is a single item: “My eye condition limits my physical 
ability to do the things I want to do” 
- each item is scored as follows: 1= never/almost never; 
2=sometimes; 3=often; 4=almost always 
Visual Analogue Scales 
 
  
Noticeability  - is a single item: “How noticeable do you feel your 
thyroid eye disease is to other people?” 
- scored on a 10 cm line with the following anchors: 
Not at all noticeable |..........| Very noticeable 
- scored 0-10 
- higher scores indicate greater distress 
 
Severity is a single item: “How severe do you feel your thyroid eye 
disease is?” 
- scored on a 10 cm line with the following anchors: 
Not very severe |..........| Extremely severe 
- scored 0-10 
- higher scores indicate greater distress 
 
Clinical rating 
Binary Composite 
Clinical Outcome 
Measure (BCCOM) 
- clinician-rating 
- binary composite outcome score with a positive result 
(improvement with no concomitant deterioration) versus no 
change or any deterioration (see Appendix 1) 
- deteriorated (-1), improved (1) 
Table 2. Data collection time points and their relation to participant trial 
appointments, plus study measures used at each time point, and number of 
potential participants attending each appointment (N) 
  Trial 
Appointment 
Study measures N 
St
u
d
y 
ti
m
e 
p
o
in
ts
 
1 -2 weeks 
Enrolment  
GO-QOL, WHOQOL, VAS,  
demographic data 
167 
2 0 weeks 
Randomization  
GO-QOL 133 
3 12 weeks 
Short term 
GO-QOL, WHOQOL, transition 
variables, VAS 
108 
4 48 weeks 
Long term 
GO-QOL, WHOQOL, transition 
variables, VAS, BCCOM 
102 
 
  
Table 3. Participant characteristics for Stage 1 GO-QOL Validation: internal validity 
and test re-test 
 Study time point 
Variable Enrolment (-2 weeks) Randomization (week 0) 
Sample size 142 126 
Age 48.02±11.44 48.27±11.40 
Sex (male/female) 41/101 
 
 
34/92 
Ethnicity   
Caucasian/Black 99/16 87/14 
Asian/Oriental 11/4 10/4 
Other (or not stated) 12 11 
 
  
Table 4. Item response table for GO-QOL at time point 1 (-2 weeks, enrolment). 
 
N 
Min 
score 
Max 
score 
Mean 
score 
SD 
Visual Function subscale 
VF1 Cycling 87 1 3 2.43 0.80 
VF2 Driving 103 1 3 2.19 0.81 
VF3 Walking indoors 139 1 3 2.71 0.54 
VF4 Walking outdoors 141 1 3 2.49 0.64 
VF5 Reading 140 1 3 2.01 0.70 
VF6 Watching TV 141 1 3 2.12 0.68 
VF7 Hobbies 122 1 3 2.29 0.77 
VF8 Interference with daily life 141 1 3 2.10 0.77 
Appearance subscale 
App9 Change in appearance 142 1 3 1.42 0.54 
App10 Feeling watched 142 1 3 2.14 0.77 
App11 Unpleasant reactions 140 1 3 2.49 0.68 
App12 Impact on self-confidence 142 1 3 1.73 0.72 
App13 Feeling of social isolation 142 1 3 2.50 0.69 
App14 Influence on friendships 142 1 3 2.46 0.73 
App15 Less often in photos 141 1 3 1.90 0.85 
App16 Camouflaging appearance 142 1 3 2.04 0.82 
Key: N= number of responses; SD = standard deviation 
 
  
Table 5. Item response table for GO-QOL at time point 2 (week 0, randomisation)  
 
N 
Min 
Score 
Max 
Score 
Mean 
score 
SD 
Visual Function subscale 
VF1 Cycling 75 1 3 2.59 0.68 
VF2 Driving 93 1 3 2.38 0.75 
VF3 Walking indoors 125 1 3 2.72 0.47 
VF4 Walking outdoors 126 1 3 2.61 0.61 
VF5 Reading 126 1 3 2.23 0.69 
VF6 Watching TV 126 1 3 2.36 0.66 
VF7 Hobbies 110 1 3 2.47 0.69 
VF8 Interference with daily life 126 1 3 2.28 0.73 
Appearance subscale 
App9 Change in appearance 126 1 2 1.50 0.50 
App10 Feeling watched 126 1 3 2.17 0.76 
App11 Unpleasant reactions 125 1 3 2.58 0.60 
App12 Impact on self-confidence 126 1 3 1.83 0.75 
App13 Feeling of social isolation 126 1 3 2.59 0.65 
App14 Influence on friendships 126 1 3 2.45 0.77 
App15 Less often in photos 126 1 3 2.01 0.83 
App16 Camouflaging appearance 126 1 3 2.05 0.81 
Key: N= number of responses; SD = standard deviation 
  
Table 6. CIRTED trial allocation groups. 
Group Allocation N=126 randomised 
1 Radiotherapy and Azathioprine 31 (24.6%) 
2 SHAM Radiotherapy and Azathioprine 31 (24.6%) 
3 Radiotherapy and PLACEBO 32 (25.3%) 
4 SHAM Radiotherapy and PLACEBO 32 (25.3%) 
 
  
Table 7. Participant characteristics for Stage 2: Longitudinal validation of GO-QOL 
Variable Study time point  
 Short term (12 weeks) Long term (48 weeks) 
N 108 101 
Age 49.48±10.82 49.88±10.46 
Sex (male/female) 29/79 27/73 
Ethnicity   
Caucasian/Black 79/13 72/10 
Asian/Oriental 8/4 9/4 
Other (or not stated) 4 5 
 
  
Table 8: Mean scores ± standard deviations for G0-QOL and WHOQOL-Bref across 
study time points, results for RM ANOVA with effect sizes 
Study measure Enrolment 
(-2 weeks) 
Short term 
(12 weeks) 
Long term 
(48 weeks) 
RM ANOVA 
F & p value 
Effect size  
 η2 
GO-QOL subscales: 
Visual Function 65.94 
±28.49 
72.49 
±26.64 
76.11 
±24.73 
11.034 
p<0.001 
0.114 
Medium 
Appearance 54.1  
±26.54 
58.81 
±27.25 
60.84 
±28.75 
13.061 
p=0.002 
0.069 
Small 
WHOQOL-Bref subscales: 
Physical 58.69 
±22.64 
60.93 
±21.01 
63.46 
±20.67 
3.18 
p=0.044 
0.037  
Small 
Psychological 52.66 
±21.35 
52.14 
±23.04 
57.79 
±20.20 
6.53 
p=0.002 
0.064  
Small 
Environment 66.60 
±20.03 
67.81 
±18.92 
69.15 
±17.13 
1.97 
p=0.143 
0.043 
Small 
Social Relationships 66.08 
±20.81 
60.83 
±21.53 
65.54 
±21.77 
2.99 
p=0.054 
0.041 
Small 
 
  
Table 9. Transition scores and visual analogue scales correlated with GO-QOL and 
WHOQOL scores. 
 
T1 T2 
VAS 
Noticeability 
VAS 
Severity 
Week 12 GO-QOL subscales: 
Visual Function -0.413** 0.015      -0.108  -0.117 
Appearance -0.409** -0.580** -0.587** -0.552** 
Week 12 WHOQOL-Bref subscales: 
Psychological -0.284** -0.475** -0.399**  -0.127 
Physical -0.451** -0.612** -0.383** -0.466** 
Social  -0.193 -0.307**       -0.167 -0.262* 
Environment -0.295** -0.508** -0.346** -0.253** 
     
Week 48 GO-QOL subscales: 
Visual Function -0.017 -0.162 0.014 -0.046 
Appearance -0.389** -0.574** -0.723** -0.678** 
Week 48 WHOQOL-Bref subscales: 
Psychological 0.19 0.017 -0.037 0.148 
Physical 0.149 -0.005 -0.106 -0.024 
Social 0.158 0.083 -0.151 0.089 
Environment 0.199 0.025 -0.07 0.006 
Key: ** = significant at p<.001, *= significant at p<.05 
  
Table 10. Participant characteristics for Stage 3: Exploring discriminant validity 
based on BCCOM 
Variable Study time point 48 weeks  
 -1 deteriorated +1 improved 
N 58 36 
Age 50.31±10.72 48.72±10.53 
Sex (male/female) 12/46 12/24 
Ethnicity   
Caucasian/Black 46/4 22/6 
Asian/Oriental 5/2 4/1 
Other/missing 1/0 3/0 
 
  
Table 11. Comparing means of GO-QOL & WHOQOL subscales according to BCCOM 
group (improved n=36, deteriorated n=58) at 48 week time point 
GO-QOL BCCOM group Mean±sd p  value Cohen’s d (CI) 
Visual Function +1 (improved)  83.06±21.06 
0.006 
0.6 medium      
(CI 0.19 – 1.04)  -1(deteriorated) 67.86±26.46 
Appearance +1 (improved)  64.89±28.33 
0.152 
0.3 moderate   
(CI -0.13 – 0.73)  -1 (deteriorated) 55.89±28.26 
WHOQOL     
Psychological +1 (improved)  51.73±22.32 
0.138 
0.4 moderate   
(CI -0.03 – 0.83)  -1(deteriorated) 59.61±19.29 
Physical +1 (improved)  58.08±22.27 
0.537 
0.2 small            
(CI -0.23 – 0.63)  -1(deteriorated) 61.63±22.21 
Social +1 (improved)  56.30±23.75 
0.083 
0.5 medium      
(CI -0.89 – -0.05)  -1(deteriorated) 67.34±22.96 
Environment +1 (improved)  65.08±19.66 
0.356 
0.2 small 
(CI -0.23 – 0.63)  -1(deteriorated) 69.74±19.68 
 
  
Table 12. Comparing means of GO-QOL subscales according to VAS group at 48 
week time point 
GO-QOL VAS noticeability Mean±sd p  value Cohen’s d (CI) 
Visual Function <5.0 (improved, n=45)        84.63±20.72 
0.001 
0.8 medium    
(CI 0.41 – 1.19)  >5.1(noticeable, n=54) 66.37±26.36 
Appearance <5.0 (improved, n=45)  79.86±18.17 
0.001 
1.6 very large 
(CI 1.17 – 2.03)  >5.1(noticeable, n=55) 45.23±25.11 
 VAS severity    
Visual Function <5.0 (improved, n=53)  84.00±20.46 
0.001 
0.8 medium 
(CI 0.41 – 1.19)  >5.1(severe, n=45) 64.54±26.71 
Appearance <5.0 (improved, n=53)  74.29±23.14 
0.001 
1.2 large          
(CI 0.77 – 1.63)  >5.1(severe, n=46) 46.06±25.60 
 
 
